Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel

European Journal of Gynaecological Oncology

Volumn 26, Issue 3, 2005, Pages 285-287

  Balbi, G C ^a,b   Cardone, A ^a   Passaro, M ^a   Battista, M ^a   Monteverde, A ^a   Visconti, S ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

CA 125; Ovarian cancer; Paclitaxel; Platinum

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL; PLATINUM;

ACCURACY; ARTICLE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVARY CARCINOMA; PREDICTION; SENSITIVITY AND SPECIFICITY; STANDARD;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT SELECTION; PLATINUM COMPOUNDS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 21044453737     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rustin J.G., Marples M., Nelstrop A.E. et al.: "Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels". J. Clin. Oncol., 2001, 19, 4054.
2. Fayers P.M., Rustin G., Wood R. et al.: "The prognostic value of serum CA-125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynecological Cancer". Int. J. Gynaecol. Cancer, 1993, 3, 285.
3. Miller A.B., Hoogstraten B., Staquet M. et al.: "Reporting results of cancer treatment". Cancer, 1981, 47, 207.
4. Jacobs I.J., Rivera H., Oram D.H. et al.: "Differential diagnosis of ovarian cancer with tumour markers CA-125, CA-15-3 and TAG-72.3". Br. J. Obstet. Gynaecol., 1993, 100, 1120.
5. Krebs H.B., Goplerud D.R., Kilpatrick S.J. et al.: "The role of CA-125 as a tumour marker in ovarian cancer". Obstet. Gynecol., 1986, 67, 473.
6. Rustin G.J., Nelstrop A.E., Tuxen M.K. et al.: "Defining progression of ovarian carcinoma during follow-up according to CA-125: A North Thames Ovary Group Study". Ann. Oncol., 1996, 7, 361.
7. Rustin G.J., Nelstrop A., Stilwell J. et al.: "Savings obtained by CA-125 measurements during therapy for ovarian carcinoma: The North Thames Ovary Group". Eur. J. Cancer, 1992, 28, 79.
8. Rustin G.J.S.: "Use of CA-125 to assess response to new agents in ovarian cancer trial". J. Clin. Oncol., 2003, 15, 187.
9. Rustin J.G., Nelstrop A.E., McClean P. et al.: "Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125". J. Clin. Oncol., 1996, 14, 1545.
10. Vergote I.B., Bormer O.P., Abeler V.M.: "Evaluation of serum CA-125 levels in the monitoring of ovarian cancer". Am. J. Obstet. Gynecol., 1987, 157, 88.
11. Altaras M.M., Goldberg G.L., Levin W. et al.: "The role of cancer antigen 125 (CA-125) in the management of ovarian epithelial carcinomas". Gynecol. Oncol., 1988, 30, 26.
12. Guppy A.E., Rustin G.J.S.: "CA-125 response: can it replace the traditional response criteria in ovarian cancer?". Oncologist, 2002, 7, 437.
13. Therasse P., Arbuck S.G., Eisenhauer E.A. et al.: "New guidelines to evaluate the response to treatment in solid tumours". J. Natl. Cancer Inst., 2000, 92, 205.
14. Vergote I., Rustin G.J.S., Eisenhauer E.A. et al.: "Reply to: New guidelines to evaluate the response to treatment in solid tumours (ovarian cancer)" (letter). J. Natl. Cancer Inst., 2000, 92, 1534.
15. McIntosh M.W., Drescher C., Karlan B. et al.: "Combining CA-125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma". Gynecol. Oncol., 2004, 95, 9.
16. Tammela J., Lele S.: "New modalities in detection of recurrent ovarian cancer". Curr. Opin. Obstet. Gynecol., 2004, 16, 5.
17. Maggino T. et al.: "Prospective multicenter study on CA-125 in postmenopausal pelvic masses". Gynecol. Oncol., 1994, 54, 117.
18. Davelaar E.M., Bonfrer J.M., Verstraeten R.A. et al.: "CA-125: A valid marker in ovarian carcinoma patients treated with paclitaxel?". Cancer, 1996, 78, 118.
19. Eisenhauer E.A., ten Bokkel Huinink W.W. et al.: "European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion". J. Clin. Oncol., 1994, 12, 2654.
20. Pearl M.L., Yashar C.M., Johnston C.M. et al.: "Exponential regression of CA-125 during salvage treatment of ovarian cancer with taxol". Gynecol. Oncol., 1994, 53, 339.
21. Bridgewater J.A., Nelstrop A.E., Gordon J.S. et al.: "Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel". J. Clin. Oncol., 1999, 17, 501.
22. Isonishi S.: "Biomarker in gynaecologic malignancies" (abstract). Gan To Kagaku Ryoho, 2004, 31, 1003.
23. Jacobs I.J., Skates S., Davies A.P. et al.: "Risk of diagnosis of ovarian cancer after raised serum CA-125 concentration: a prospective cohort study". Br. Med. J., 1996, 313, 1355.
24. Gore M.E., Cooke J.C., Wiltshaw E. et al.: "The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary". Br. J. Cancer, 1989, 60, 751.